Based on the preclinical studies, MEK inhibitors could improved T cell activation, conditioned the tumor microenvironment to facilitate improved response to anti-CTLA-4 treatment and prolonged survival in KRAS-mutant mice in combination with CTLA-4 blockade [54, 55]. This evidence concerns the gene CTLA4 and neoplasm.